Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?
Choon Ok Kim,1 Eun Sil Oh,2 Hohyun Kim,3 Min Soo Park1,4 1Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul, 2Department of Pharmaceutical Medicine and Regulatory Sciences, College of Medicine and Pharmacy, Yonsei University, Incheon, 3Korea Medic...
Main Authors: | Kim CO, Oh ES, Kim H, Park MS |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-02-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/pharmacokinetic-interactions-between-glimepiride-and-rosuvastatin-in-h-peer-reviewed-article-DDDT |
Similar Items
-
Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis
by: Thakkar D, et al.
Published: (2017-04-01) -
Influence of <it>SLCO1B1 </it>and <it>CYP2C8 </it>gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers
by: Aquilante Christina L, et al.
Published: (2008-09-01) -
Effects of <i>SLCO1B1</i> and <i>SLCO1B3</i> Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
by: Gonjin Song, et al.
Published: (2021-08-01) -
A cost effective RFLP method to genotype Solute carrier organic anion 1B1 (SLCO1B1) c.1929A>C (p.Leu643Phe, rs34671512); a variant with potential effect on rosuvastatin pharmacokinetics
by: Nyarai D. Soko, et al.
Published: (2018-06-01) -
Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects
by: Woo HI, et al.
Published: (2017-04-01)